

NEWSLETTER ISSUE 34 25 -31 AUGUST 2018

ACADEMIC ACTIVITIES

Publications of the week

1. Mahadevappa, R., Neves, H., Yuen, S. M., Jameel, M., Bai, Y., Yuen, H. F., Zhang, S. D., Zhu, Y., Lin, Y., and Kwok, H. F. (2018) DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer. *Cancers (Basel)* **10**

2. Wang, F., Zhang, Q. E., Zhang, L., Ng, C. H., Ungvari, G. S., Yuan, Z., Zhang, J., Zhang, L., and Xiang, Y. T. (2018) Prevalence of major depressive disorder in older adults in China: A systematic review and meta-analysis. *J Affect Disord* **241**, 297-304

3. Wang, G., Zheng, W., Li, X. B., Wang, S. B., Cai, D. B., Yang, X. H., Ungvari, G. S., Xiang, Y. T., and Correll, C. U. (2018) ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. *J Psychiatr Res* **105**, 23-32

4. Wang, H., Pardeshi, L. A., Rong, X., Li, E., Wong, K. H., Peng, Y., and Xu, R. H. (2018) Novel Variants Identified in Multiple Sclerosis Patients From Southern China. *Front Neurol* **9**, 582

5. Yan, L., Jiang, B., Niu, Y., Wang, H., Li, E., Yan, Y., Sun, H., Duan, Y., Chang, S., Chen, G., Ji, W., Xu, R. H., and Si, W. (2018) Intrathecal delivery of human ESC-derived mesenchymal stem cell spheres promotes recovery of a primate multiple sclerosis model. *Cell Death Discov* **5**, 28

Seminar Series

The Promises and Challenges of Non-coding RNA Studies in Neurodegenerative Diseases - Prof. Hermona SOREQ



Prof. Hermona SOREQ, Professor from the Hebrew University of Jerusalem, Israel, visited FHS and shared her views on the promises and challenges of Non-coding RNA Students in neurodegenerative disease.

In the seminar, Prof. SOREQ talked about noncoding RNAs including the molecular regulators of acetylcholine functioning, that are often modified under traumatic stress and neurodegenerative diseases. She shared that her team combine experimental and analytic research tools to study the small microRNA genes and identified primate-specific microRNA controllers that operate via suppressing acetylcholinesterase to protect brain and body from Alzheimer's and Parkinson's diseases. The findings demonstrate experimental manipulation of these phenotypes by antisense oligonucleotides and open new venues for personalized diagnosis and therapeutic intervention.



NEWSLETTER ISSUE 34 25 -31 AUGUST 2018

ACADEMIC ACTIVITIES

Seminar Series Dissection of the role of cell type specific histamine receptors in central nervous system disorders - Prof. Zhong CHEN

Prof. Zhong CHEN, Professor of Zhejiang University visited FHS and shared his latest research on the role of cell type specific histamine receptors in central nervous system (CNS) disorders.

In the seminar, Prof. CHEN discussed his work on histamine receptors. His team generated mice with selective deletion of histamine receptors in different types of neuron and glia to dissect the role of cell type specific histamine receptors in CNS disorders.



They discovered that histamine H2/H3 receptors in neurons, H1/H2 receptors in astrocytes, H2 receptors in oligodendrocytes are implicated in the process of excitotoxicity, neuronal autophagy, glial scar formation and remyelination following cerebral ischemia. He explains that in-depth understanding of the potential action of cell type specific histamine receptors is the necessary stepping stone to unlock the wide-ranging applications of histamine related agents in the clinical arena.

Seminar Series

Al Directed CTL Vaccine Design for a Novel Synthetic Vaccine Platform - Dr. Reid M. RUBSAMEN



Dr. Reid M. RUBSAMEN, M.D., CEO of Flow Pharma, Inc. visited FHS and shared his experience on AI Directed CTL Vaccine Design for a Novel Synthetic Vaccine Platform.

Flow Pharma is a San Francisco-based biotechnology company using Al-augmented proteomics analytical techniques to select Class I epitopes for the inclusion into a novel synthetic vaccine platform for immuno oncology and infectious disease applications. The lead products under development are FlowVax HPV for treating women with advanced cervical cancer and FlowVax EBOV for protection against Ebola infection.





SEPTEMBER				
Mon	Tues	Wed	Thurs	Fri
3	4 PhD Oral Defense Houliang DENG Time: 10:00 Venue: N6- G010	5 Seminar Series Prof. Cheng-Hang LIU Time: 11:00-12:00 Venue: E12- G004 AC Meeting Time: 15:00-17:00 (Tentative) Venue: E12-G004 B-CAT Meeting #25 Prof. Wei GE Time: 17:00 Venue: E12-G004	6 FHS Postdoc/ Student Seminar Series Host: Ren-he XU Joong Sup SHIM Time: 17:00 Venue: E12-G003	7
10	11	12 <u>Macau Stem Cell</u> <u>Symposium</u> Time: 09:00-18:00 Venue: E12-G004	13	14
17	18	19 B-CAT Meeting #26 Prof. Hongjie ZHANG Time: 17:00 Venue: E12-G004	20 FHS Postdoc/ Student Seminar Series Host: Guokai CHEN Henry KWOK Time: 17:00 Venue: TBC	21 Seminar Series Overcoming challenges to CRISPR-mediated gene correction for treating genetic airway diseases Prof. Jim HU Time: 09:30-10:30 Venue: TBC
24	25	26	27	28

For more information or submission of articles to be featured, please contact Ms. Vivienne Fong at viviennefong@umac.mo or 8822 4230.